FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency
With Alnylam’s rolling application for its landmark RNA therapy patisiran just weeks from completion, the FDA has come through with a breakthrough drug designation that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
